Month: August 2024

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024. “The second quarter financial results demonstrate the true earnings power of the Vertex business model,” stated David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “We were GAAP earnings positive for the third quarter in a row, generated the highest level of quarterly cash provided by operating activities and free cash flow in our 46-year history and delivered our highest Adjusted EBITDA margin since we became a public company over four years ago.” DeStefano continued, “These are strong financial results, but we are just getting started. Several strategic...

Year-to-date consolidated earnings reflect strength of core utility operations Confirming consolidated earnings guidance of $2.36 to $2.56 per diluted share Continued investment in system improved reliability during recent heat waveSPOKANE, Wash., Aug. 07, 2024 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today announced financial results for the second quarter of 2024. Net income and earnings per diluted share for the second quarter and year-to-date 2024 compared to the same periods in 2023 are presented in the table below (dollars in thousands, except per-share data):   Second Quarter     Year-to-Date    2024     2023     2024     2023  Net Income (Loss) by Business Segment:                      Avista Utilities $ 23,935     $ 18,810     $ 91,443     $ 70,437  AEL&P   1,109       1,359       5,020       5,401  Other   (2,186 )     (2,685 )     (2,110 )     (3,509 )Total...

– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the second quarter of 2024 and provided an update on recent company developments. “We are very pleased with the continued strong momentum of our U.S. launch of OGSIVEO for adults with desmoid tumors....

MORRISVILLE, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the second quarter ended June 30, 2024. The company will host a webcast at 8:30 a.m. ET on August 7, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “We continue to face no legal impediments for the FDA approval of YUTREPIA for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and our commercial team stands ready to launch YUTREPIA contingent on the FDA’s final approval. If approved, we firmly believe that the ease of administration and...

Second Quarter 2024 Overview (all comparisons are made to the corresponding prior year second quarter unless otherwise specified):Net sales of $345.5 million decreased 1.3% from the record sales in the prior year. Implied orders increased 5.9% sequentially from the first quarter. Inventory initiatives drove $28.7 million sequential reduction from the first quarter. Diluted EPS of $(0.61), which included an $0.89 per share impact related to goodwill impairment, compared to $0.58; Adjusted EPS of $0.61 compared to $0.87. Backlog of $531.1 million as of June 30, 2024. Federal highway bill spending in the early stages of deployment, with only ~ 20% funds disbursed and 38% committed. Total state budgets are up 12% year-over-year in fiscal year 2024 following an 11% increase in fiscal year 2023.CHATTANOOGA, Tenn., Aug. 07, 2024 (GLOBE...

Revenue of $627.0 million and Direct-to-Consumer (“DTC”) Revenue of $173.7 millionDTC Platforms Revenue Increased 1.3% Sequentially and 5.1% Year Over YearGAAP Net Income of $86.6 million and Credit Adj. EBITDA of $191.0 million HERZLIYA, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) — Playtika Holding Corp. (NASDAQ: PLTK) today released financial results for its second quarter for the period ending June 30, 2024. Financial HighlightsRevenue of $627.0 million decreased (3.7)% sequentially and (2.5)% year over year. DTC platforms revenue of $173.7 million increased 1.3% sequentially and 5.1% year over year. Net income of $86.6 million increased 63.4% sequentially and 14.4% year over year. Credit Adjusted EBITDA of $191.0 million increased 2.9% sequentially and decreased (11.2)% year over year. Cash, cash equivalents, and short-term investments...

Growth Rates Accelerate in Q2 and FY 2024Q2 2024 and FY 2024 Key HighlightsQ2 Financials – Beat on Revenues, ex-TAC and Adj. EBITDA; Growth rates accelerateQ2 2024 Results: Revenues $428M, Gross profit $115M, ex-TAC Gross Profit $150M, Net loss $4M, Non-GAAP Net Income $23M, Adj. EBITDA $37M, Free Cash Flow $26M Strong YoY growth: Revenues +29%, ex-TAC +21%, Adj. EBITDA +138%, FCF +237% Strong Free Cash Flow conversion: 70%+ from Adj. EBITDAReiterating 2024 ex-TAC, Adj EBITDA, FCF Guidance; Growth rates accelerate across all metricsInitiating Q3 guidance: $431M in Revenues (+20% YoY), $134M Gross profit (+33% YoY), $164M ex-TAC Gross Profit (+28% YoY), $47M Adj. EBITDA (+106% YoY)* Reiterating 2024 guidance: $667M ex-TAC Gross Profit (+25% YoY), $200M+ Adj. EBITDA (2x+ YoY; ~30% margin), $100M+ FCF (~2x...